OverT Bio is at the forefront of developing innovative cellular therapies aimed at treating solid tumors. The company leverages advanced scientific methodologies, including pooled functional screening and synthetic genomics, through its proprietary platforms known as OverTarget™ and OverTune™. These technologies enable the engineering of immune cells to enhance their effectiveness against cancer. OverT Bio's commitment to scientific rigor is evident in its collaborations with a team of immunologists and genome engineers, as well as its backing from prominent TechBio investors.

The scientific advancements made by OverT Bio have been recognized in prestigious publications, underscoring the credibility and impact of their research. Notable studies published in journals such as Nature and The New England Journal of Medicine highlight the company's innovative approaches, including genome-scale screening for T cell proliferation and multiomics-guided cellular immunotherapies. This body of work not only showcases OverT Bio's dedication to advancing cancer treatment but also positions the company as a leader in the field of immunotherapy.

United States

OverT Bio is a biotech company focused on developing cell therapies for solid tumors. The company aims to enable the curative potential of cell therapies through innovative genetic modifications and reprogramming of immune cells.

OverT Bio

Company Details